Skip to main content

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Safety and Efficacy of Vaccination With Folate Receptor Alpha for Ovarian Cancer

Roisin O'Cearbhaill, MD, Memorial Sloan Kettering Cancer Center, New York, discusses a phase 2 trial evaluating the safety and efficacy of TPIV200 versus GM-CSF alone in patients with high-grade, platinum-sensitive ovarian cancer, the data of which were presented at the virtual 2020 ASCO Annual Meeting.

Advertisement

Advertisement

Advertisement

Advertisement